Advancing innovative precision therapeutics for debilitating and rare diseases

CANACCORD GENUITY 42ND ANNUAL GROWTH CONFERENCE

August 11, 2022

QUINCE THERAPEUTICS

Forward-looking statements

Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this presentation may be identified by the use of words such as “expect,” “will,” “estimate,” “project,” “potential,” “positioned,” "advancing," "planned," "progression," "targeting," "allow," "identify," "concluding," "leader," "progress," "underway," "goal,“ or other similar words. Examples of forward-looking statements include, among others, clinical development and strategic development path for NOV004; cash runway and the ability to fund clinical development milestones; the company’s plans to pursue the strategic expansion of its development pipeline, its intent to out-license its legacy neuroscience and antiviral assets, the strategic growth plan, the FDA and clinical development plans and timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company’s product candidate and discovery pipeline; and statements about its ability to obtain, and the timing relating to, further development and/or out-licensing of its legacy neuroscience and antiviral assets, regulatory submissions, and related response and decisions. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this presentation are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.

QUINCE THERAPEUTICS

Advancing innovative precision therapeutics for debilitating and rare diseases

- ✓ *Addressing major, unmet medical needs across multiple skeletal therapeutic indications*
- ✓ *Highly differentiated bone-targeting drug platform and broad applicability of lead molecule NOV004*
- ✓ *Strategic pipeline expansion through opportunistic in-licensing and acquisition of clinical-stage assets*
- ✓ *Strong cash position expected to fund operations and clinical activities into the second half of 2025*
- ✓ *Out-licensing legacy neuroscience and antiviral assets*
- ✓ *Proven and seasoned team with track record of success*

Highly differentiated precision bone disease platform



- Capable of delivering small molecules, peptides, or large molecules
- Designed to deliver concentrated drug directly to the site of fracture, disease, and infection
- Promotes more rapid healing with fewer off-target safety concerns in preclinical studies
- More than 10 years of preclinical studies de-risk development path
- Positioned to address major, unmet medical needs across multiple skeletal indications

NOV004 discovered at Low lab at Purdue University

Therapeutic Agent

- Abaloparatide payload
- Parathyroid hormone related protein
- Increases bone density and approved for osteoporosis

Biological Linker

- Links targeting ligand to abaloparatide payload
- Short sequence of amino acids
- Allows payload to interact with receptors on nearby cells

Targeting Ligand

- Concentrates abaloparatide payload at fracture site
- Sequence of negatively charged glutamic acid
- Binds to hydroxyapatite with high affinity at site of bone trauma



Uniquely engineered structure delivers anabolic that accelerates repair directly to fracture site

NOV004 targeting to fracture site increases half-life

	Drug and Site	Half-Life (Hours)
Non-targeted Drug	Contralateral Femur	1.6
	Fractured Femur	8.8
NOV004	Contralateral Femur	5.7
	Fractured Femur	**66.4**

NOV004 accumulates at fracture site leading to 10X AUC compared to non-targeted drug

Half-Life of NOV004 in Bone



Preclinical evidence of NOV004 advantage





- 2-fold **new bone** growth vs. free drug and 3-fold vs. vehicle
- BMD almost twice as **dense** in bone treated with NOV004 vs. non-targeted drug
- Strength to re-fracture statistically significant vs. free drug and vehicle
- Results reproduced in mice, rats, and dogs – as well as osteoporotic, diabetic, and osteogenesis imperfecta mice
- Post-fracture NOV004 treated mice have improved function with earlier, farther, and faster movement

Leading innovator with strong intellectual property

Foundation

8 patent families covering covering 80+ anabolic agents and 25+ targeting molecules

Breadth

Genus claims cover major and minor bone anabolic pathways

Depth

Granted composition of matter claims covering NOV004 and lead compounds

– Coverage of NOV004 and uses until 2041+

Markets

Global coverage including US, Europe, Japan, Australia, Canada, China

Opportunistic in-licensing & acquisition of clinic-stage assets

- Evaluating clinical-stage assets targeting debilitating and rare diseases
- Must have compelling clinical data, strong commercial opportunity, and clear operational synergy
- Disciplined approach with ability to be selective and competitive



Proven and seasoned leadership team

Dirk Thye, M.D.

- 20+ years of experience in biotech company creation, R&D and executive leadership
- Agenovir, Cidara, Cerexa and Peninsula

CEO

Karen Smith, M.D., Ph.D., M.B.A., LL.M

- Previously CMO at Emergent and Jazz
- Led 50+ clinical trials and 20+ product or indication approvals

CMO

Brendan Hannah, M.B.A.

- 5+ years leading biotech business operations
- Led BD at Agenovir (acquired by Vir for up to $290M) and involved in $1B+ in other transactions

CBO

Stewart A. Low, Ph.D.

- Primary inventor of precision bone disease platform IP
- Visiting scholar, Purdue University

Head of Discovery

Ted Monohon

- 20+ years financial experience in private equity, publicly/privately held companies and major banks
- Deloitte, SOA Projects, X10 Capital Management

CAO

Collective experience represent 20+ regulatory approvals and more than $20 billion in aggregate acquisitions

QUINCE THERAPEUTICS

Investment summary

- ✓ *Addressing major, unmet medical needs across multiple skeletal therapeutic indications*
- ✓ *Highly differentiated bone-targeting drug platform and broad applicability of lead molecule NOV004*
- ✓ *Strategic pipeline expansion through opportunistic in-licensing and acquisition of clinical-stage assets*
- ✓ *Strong cash position expected to fund operations and clinical activities into the second half of 2025*
- ✓ *Out-licensing legacy neuroscience and antiviral assets*
- ✓ *Proven and seasoned team with track record of success*